Epithelial-mesenchymal transition (EMT) beyond EGFR mutations per se is a common mechanism for acquired resistance to EGFR TKI-Reference-Cited by-同舟云学术

Epithelial-mesenchymal transition (EMT) beyond EGFR mutations per se is a common mechanism for acquired resistance to EGFR TKI

Published:2018-08-15 Issue:4 Volume:38 Page:455-468
ISSN:0950-9232
Container-title:Oncogene
language:en
Short-container-title:Oncogene

Author:

Weng Chien-Hui,Chen Li-Yu,Lin Yu-Chin,Shih Jin-Yuan,Lin Yun-Chieh,Tseng Ruo-Yu,Chiu An-Chieh,Yeh Yu-Hsuan,Liu Chi,Lin Yi-Ting,Fang Jim-Min,Chen Ching-Chow

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Genetics,Molecular Biology

Link

http://www.nature.com/articles/s41388-018-0454-2.pdf

Reference48 articles.

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2010;60:277–300.

2. Locke I, Gillham CM. Chemotherapy for lung cancer. N Engl J Med. 2002;346:1498. author reply

3. Pao W, Kris MG, Iafrate AJ, Ladanyi M, Janne PA, Wistuba II, et al. Integration of molecular profiling into the lung cancer clinic. Clin Cancer Res. 2009;15:5317–22.

4. Sequist LV, Bell DW, Lynch TJ, Haber DA. Molecular predictors of response to epidermal growth factor receptor antagonists in non-small-cell lung cancer. J Clin Oncol. 2007;25:587–95.

5. Janne PA. Ongoing first-line studies of epidermal growth factor receptor tyrosine kinase inhibitors in select patient populations. Semin Oncol. 2005;32:S9–S15.

Cited by 175 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Mechanistic insights into Yifei Sanjie pill's regulation of EMT to enhance gefitinib treatment effect in NSCLC by in silico analysis and experimental validation;Journal of Ethnopharmacology;2024-11

2. Targeting non-coding RNAs to overcome osimertinib resistance in EGFR-mutated non-small cell lung cancer;Frontiers in Oncology;2024-09-11

3. PIM1 kinase promotes EMT-associated osimertinib resistance via regulating GSK3β signaling pathway in EGFR-mutant non-small cell lung cancer;Cell Death & Disease;2024-09-03

4. Cancer drug-tolerant persister cells: from biological questions to clinical opportunities;Nature Reviews Cancer;2024-09-02

5. Mechanisms of resistance to tyrosine kinase inhibitor‐targeted therapy and overcoming strategies;MedComm;2024-08-24